Dr. Shadman on the Role of MRD in CLL

Video

Mazyar Shadman, MD, a physician and associate professor in the Divisions of Medical Oncology and Clinical Research at Seattle Cancer Care Alliance, discusses the role of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL).

In the post-chemotherapy era, MRD primarily applies to venetoclax (Venclexta)-based regimens, according to Shadman. However, it's important to understand that standard treatment strategies are not based on MRD status, Shadman adds; however, there is currently a lot of academic interest in the marker, so its role in the paradigm may become more pronounced in the future.

Currently, in a clinical setting, Shadman utilizes FDA-approved standards of care. For example, when using a combination of venetoclax and obinutuzumab (Gazyva) in the frontline setting, treatment should be stopped at 1 year, Shadman explains. Although data from the phase 3 CLL14 trial (NCT02242942) indicated that MRD may have predictive value, it shouldn't currently be changing treatment approaches, Shadman concludes.

Related Videos
Jennifer Brown, MD, PhD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Tatyana Feldman, MD
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
Michael Choi, MD, UCSD Health
Tatyana Feldman, MD
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk